Bringing Medical Aesthetics Production In-House

GC Wellbeing said on November 3 that it held a groundbreaking ceremony for its medical device GMP plant in Eumseong, North Chungcheong Province, on November 2, and began building its own production capabilities to expand its medical aesthetics business.


The investment is aimed at applying the manufacturing technologies and quality control capabilities GC Wellbeing has developed in the prescription drug sector to the medical aesthetics field, and establishing in-house production systems for fillers and skin boosters. The company plans to strengthen its quality and supply competitiveness through the project and lay the foundation for mid- to long-term growth in its medical aesthetics business.


GC Wellbeing held a groundbreaking ceremony for its medical device GMP plant in Eumseong, North Chungcheong Province, on the 2nd, officially beginning work to establish its own production base and expand its medical aesthetics business. GC Wellbeing

GC Wellbeing held a groundbreaking ceremony for its medical device GMP plant in Eumseong, North Chungcheong Province, on the 2nd, officially beginning work to establish its own production base and expand its medical aesthetics business. GC Wellbeing

View original image

The new production facility will be built within GC Biopharma's Eumseong Plant and is expected to include a prefilled syringe (PFS) filling line and quality testing facilities. It will also include space for expansion to accommodate future production of new products, preparing the company to broaden its product portfolio.


The facility is expected to strengthen the company's in-house production and quality control capabilities for fillers and skin boosters and ensure a stable supply system. GC Wellbeing plans to continue expanding its product lineup, including a next-generation skin booster currently in development, and to manufacture products that are commercialized in the future at the new facility.



Kim Sanghyun, CEO of GC Wellbeing, said, "Drawing on the aseptic manufacturing technologies and GMP-based quality control capabilities we have developed in the prescription drug sector, we will build a production system that enables us to manage product quality directly and increase customer trust."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing